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Summary: We investigated deletion polymorphism in the gene for angiotensin-converting enzyme in patients with
angiographically verified cerebral atherosclerosis. Genotypes were determined by the polymerase chain reaction
with oligonucleotide flanking of the polymorphic region of intron 16 of the angiotensin-converting enzyme gene.
Results of angiotensin-converting enzyme genotyping showed 46% of 50 studied patients to be homozygous for
the DD allele, whose prevalence was significantly increased as compared with a group of controls without athero-
sclerotic changes. In this control group, the following genotypes were observed (%): II = 24, ID = 52 and
DD = 24. The frequency of the I and D alleles in the group of patients with cerebral atherosclerosis was 0.28 and
0.72, respectively, whereas in the group without atherosclerosis it was 0.50 for both. Furthermore, in the present
study, the DD genotype was associated with a high level of serum angiotensin-converting enzyme activity, total
and LDL-cholesterol and triacylglycerol. A newly established association between DD genotype and cerebral athero-
sclerosis, detected even in our small group, supports the view that angiotensin-converting enzyme polymorphism
might be indicative of the development of cerebral atherosclerosis.
Introduction
Cerebrovascular insufficiency is a multifactorial dis-
ease, influenced by risk factors such as disturbance
of the lipid profile, gene polymorphism and blood
pressure (1).
The renin-angiotensin system plays a major role in
haemodynamic and fluid balance homeostasis. Renin1),
a proteolytic enzyme, acts on angiotensinogen to gener-
ate the inactive prohormone angiotensin I. Angiotensin-
converting enzyme1), a dipeptidyl carboxypeptidase,
converts angiotensin I to a vasoconstrictor octapeptide,
angiotensin II. Angiotensin-converting enzyme is re-
sponsible for the degradation of vasodilator kinins such
as bradykinin.
Angiotensin-converting enzyme is mainly located on
the endothelium of blood vessels, but it is also found
in epithelial cells, blood mononuclear cells and macro-
phages (2). In recent years, there has been a renewed
interest in the role of angiotensin II in smooth muscle
cell proliferation, since data have been reported, sug-
gesting that the inhibition of formation of angiotensin
1 Enzymes:
Renin= EC 3.4.23.15
Angiotensin-converting enzyme: Peptidyl-dipeptidase A,
EC 3.4.15.1
II by angiotensin-converting enzyme inhibitors sup-
presses arterial lesion growth (3). In addition, several
studies have assessed the effect of angiotensin-convert-
ing enzyme inhibitors. Administration of an angioten-
sin-converting enzyme inhibitor can decrease the for-
mations of angiotensin II and the breakdown of brady-
kinin, thus reducing the risk of recurrent disease (45
5). The angiotensin-converting enzyme gene has been
cloned, and the gene effect shown to be associated
with an insertion (I)/deletion (D) polymorphism of an
Alu repeat in intron 16 of the angiotensin-converting
enzyme gene. The I allele of the angiotensin-convert-
ing enzyme gene carries an intronic insertion not pre-
sent in the D allele (6—8). Recent studies have shown
angiotensin-converting enzyme polymorphism in the
angiotensin I converting enzyme gene to be closely
associated with some diseases. Zee et al. have deter-
mined the genotypes in patients with essential hyper-
tension (9). Cambien et al. have suggested that a
deletion polymorphism in the gene encoding angioten-
sin converting enzyme might be a risk factor for myo-
cardial infarction, particularly in patients ordinarily
considered at low risk for cardiovascular disease (10).
The renin-angiotensin system and angiotensin-convert-
ing enzyme polymorphism have been shown to be
associated with patients with ischaemic or idiopathic
dilated cardiomyopathy (11, 12).
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To our knowledge, no investigation of angiotensin-con-
verting enzyme I/O polymorphism in patients with cere-
bral atherosclerosis has been published to date. The pre-
sent study was undertaken to investigate the possible
relationship between homozygosity of the deletion allele
and cerebral atherosclerosis.
Materials and Methods
The subjects were patients grouped for determination of biochemi-
cal risk factors for atherosclerosis, as well as angiography of the
aortic arch and arteries proceeding to the brain; they were selected
for suspected cerebrovascular insufficiency due to atherosclerotic
changes in major cerebral arteries. Before they were sent for the
final clinical diagnostic examination, all patients were tentatively
diagnosed as having cerebrovascular insufficiency. The laboratory
and angiographic examination applied in this investigation is used
in the routine examination of patients affected by cerebral isch-
aemia, with the purpose of determining and grading atherosclerotic
changes in cerebral arteries, and establishing a therapy plan.
A total of 75 subjects, 40 males and 35 females, aged 28-76 years,
were included in the study. On the basis of angiography of the
cerebral arteries, they were divided into a group with atherosclero-
sis of the cerebral arteries and a control group.
The control group comprised 25 patients of both sexes with angio-
graphically excluded atherosclerotic changes in cerebral and pe-
ripheral arteries. Angiography was performed because cerebrovas-
cular insufficiency was suggested by certain symptoms, and by the
blood flow in the cerebral arteries determined by ultrasonography
or radioactive isotopes (angioscintigraphy). Since angiography
showed the cerebral arteries to be normal, the results from the
blood flow determination of the cerebral arteries were falsely posi-
tive, and it was concluded that the symptoms were not caused by
atherosclerosis of the cerebral arteries.
Analyses included clinical data on sex, age, lipid and lipoprotein
level, angiotensin-converting enzyme-typing and systolic and dia-
stolic blood pressure. In both groups, the medical history, the clin-
ical survey and the electrocardiogram analysis offered no evidence
of the presence of coronary heart disease. Blood pressure was mea-
sured by the standard cuff technique at rest.
Angiotensin-convert ing enzyme genotype analysis
Molecular analysis of the angiotensin-converting enzyme genotype
of patients with cerebral atherosclerosis was performed by selective
amplification of the polymorphic region in intron 16 of the angio-
tensin-converting enzyme gene (Alu repetitive sequence) by the
polymerase chain reaction and gel electrophoresis.
Blood was taken with EDTA as anticoagulant. Erythrocytes were
lysed and the pellet of nuclear leukocytes was used for isolation of
DNA. Proteinase K was then added to the leukocytes, and the phe-
nol-chloroform extraction of nucleic acids and precipitation with
ethanol were performed. In vitro enzymatic amplification of DNA
was carried out by mixing 1 μg of genomic DNA, 10 pmol of
primers (5-CTGGAGACCACTCCCATCCTTTCT-3 and
5-ATGTGGCCATCACATTCGTCAGAT-3) in a final volume of
50 μΐ, containing 3 mmol/1 MgCU, 50 mmol/1 KC1, 10 mmol/1 Tris-
HC1 pH 8.4, 0.1 g/1 gelatin, 0.5 mmol/1 dNTP (Boehringer-Mann-
heim) and 1.25 U Taq polymerase (13). DNA was amplified for 35
reaction cycles, each cycle consisting of denaturation l min at
94 °C, primer annealing l min at 58 °C and polymerisation 2 min
at 72 °C using a Thermocycler (B. Braun-biomed) (14). DNA am-
plification was followed by the analysis of the PCR product by
submarine gel electrophoresis. An amount of 10 μΐ was applied to
a 20 g/1 agarose gel and submitted to electrophoresis for 2 h at
75 V. The gel was then stained with ethidium bromide, illuminated
with short-wave ultraviolet light, and photographed.
The reaction product was a 490 base pair fragment in the presence
and a 190 base pair fragment in the absence of insertion.
Serum angiotensin-converting enzyme measurement
Serum angiotensin-converting enzyme activity was measured by a
photometric method based on the quantification of hippuric acid
from the substrate hippuryl-histidyl-leucine (15).
Lipid and lipoprotein analysis
Biochemical risk factors included the determination of plasma cho-
lesterol, triacylglycerols, HDL-cholesterol and LDL-cholesterol.
Plasma total and high density lipoprotein (HDL) cholesterol and
triacylglycerols were measured enzymatically using commercial
test kits (Boehringer-Mannheim) on an Abbott Spectrum analyser.
HDL-cholesterol was determined after selective precipitation of
LDL and VLDL with polyethylene glycol (16). Data were com-
piled according to genotype, and allele frequencies were calculated.
Differences between the groups were analysed by the Mann &
Whitney method. A value of p < 0.05 was considered significant.
Results
Results of the angiotensin-converting enzyme genotype
analysis are shown in figure 1. Homozygotes had a frag-
ment of 490 base pairs if the repeat was present or 190
base pairs if the repeat was not present. Heterozygotes
showed both fragments. Genotype frequencies according
to the presence or absence of the repeat are compared
with those of the controls in table 1. Distribution of DD,
ID and II genotypes in the patient group was 46%, 52%
and 2%, respectively. In the control group the following
genotypes were observed: II in 24%, ID in 52% and DD
in 24%. There was an excess of DD genotype and D
allele frequency in patients with brain artery atheroscle-
rosis, as compared with controls.
Patients with DD genotype had higher total cholesterol
(tab. 2) and LDL-cholesterol, whereas the ID genotype
was associated with elevated triacylglycerol, LDL and
blood pressure, 'as compared with the control group.
1 2 3 4 Base
pairs
Fig. 1 PCR detection of the insertion/deletion polymorphism in
intron 16 of the angiotensin-converting enzyme gene.
Lane 1 molecular mass markers
Lane 2 II homozygous (490 base pairs)
Lane 3 heterozygous (490,190 base pairs) '
Lane 4 DD homozygous (190 base pairs) *
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Tab. 1 Distribution of angiotensin-converting enzyme genotypes
and allele frequencies in 50 patients with angiographically esti-
mated atherosclerotic disease of cerebral arteries, and in control













The mean levels of the plasma angiotensin-converting
enzyme catalytic concentration were 39.2 and 24.7 U/1
for DD homozygotes and ID heterozygotes, respectively,
as shown in table 2. The highest angiotensin-converting
enzyme activity was found in patients with the DD ge-
notype, while only one patient with II genotype had a
high level of angiotensin-converting enzyme activity.
Discussion
The present study compares the angiotensin-converting
enzyme I/D gene polymorphism, plasma angiotensin-
converting enzyme catalytic concentration and lipid val-
ues in patients with angiographically confirmed athero-
sclerosis of cerebral arteries. The data obtained in the
study show that 46% of patients with cerebral athero-
sclerosis were homozygous for the DD allele, indicating
an increased prevalence of DD allele as compared with
the control group. Furthermore, the ID genotype was
found to be the most frequent (52%), and the resulting
frequencies of D alleles were two and a half fold those
of the I allele. In contrast, both the I and the D allele in
the control group showed a frequency of 0.50.
The study confirms the association between the plasma
angiotensin-converting enzyme catalytic concentration
and genetic polymorphism. The angiotensin-converting
enzyme/DD genotype was associated with the highest
plasma angiotensin-converting enzyme catalytic concen-
tration in the patient group.
As expected, the mean value for total and LDL-choles-
terol in all three genotypes was higher in patients than
in controls, though the mean value for triacylglycerols
was higher in the DD genotype only.
This latter observation points to a significant association
of triacylglycerol with the DD genotype, but further re-
search into its cause is necessary.
Zingone et al. have suggested that homozygosity for de-
letion of the angiotensin-converting enzyme gene might
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and even play a role in pathogenesis of hypertension and
atherosclerosis in type II diabetes (17).
All patients which might have shown changes in the
concentration of biochemical risk factors for atheroscle-
rosis, but for other reasons, were excluded from our
study, i. e. patients with liver disease, diabetes mellitus
and diseases of the thyroid and other endocrine glands.
Results further indicated elevated blood pressure in the
DD genotypes in the patient group. However, the evi-
dence for the association of angiotensin-converting en-
zyme insertion/deletion polymorphism and atherosclero-
sis is not consistent. Several studies on the relationship
between angiotensin-converting enzyme genotype and
artery disease have been performed, but the results ap-
pear to be conflicting. In a recent study, Cambien found
a close relationship between angiotensin-converting en-
zyme deletion polymorphism and the risk of myocardial
infarction in individuals considered at low risk accord-
ing to certain other factors (18). Zee et al. (1992) found
no significant differences in the distribution of the an-
giotensin-converting enzyme allele frequency between
patients with essential hypertension and control subjects
(9). Lindpaintner et al. reported that the angiotensin-
converting enzyme genotype could not be associated
with ischaemic heart disease or myocardial infarction
(19). The major finding of the present study, i.e. the
high frequency of the D allele in cerebrovascular athero-
sclerosis, is consistent with the findings of angiotensin-
converting enzyme genetic polymorphism in cardiovas-
cular atherosclerosis described by Cambien et al. This
finding points to a general significance of the angioten-
sin-converting enzyme DD genotype as a potential risk
predictor for atherosclerosis in general.
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